Every Fortune 100 company keeps a graveyard. Not of people - of projects. Technologies that worked in the lab, cleared the patents, ate years of budget, and then ran into the single most fatal question in a big company: does this fit our core business? When the answer is no, the work goes into a drawer. Catalyze Partners built a firm around opening those drawers.
Based in Dallas and founded in 2014 by the husband-and-wife team of Tricia and Joe D'Cruz, Catalyze acquires or licenses proven, market-ready technologies from large corporations and global defense programs, then does the unglamorous work of turning each one into a standalone company. It handles the funding, the hiring, the market strategy and the day-to-day operations. The corporation recoups value from research it was never going to commercialize itself. Catalyze - and its investors - own the upside.
The firm calls the target size plainly: it aims to build each acquired technology into a business worth $100 million or more. It assesses hundreds of technology assets and business units a year, and spins out only a handful.
01 / The ModelVenture capital, run in reverse
The conventional startup begins with a founder and a hypothesis, then spends years and money proving the technology works. Catalyze inverts the sequence. It starts with technology that has already survived a corporate R&D budget - meaning the hardest scientific and engineering risk is largely behind it - and builds the company afterward. What is left is commercial risk, which is the kind operators know how to manage.
There is a second inversion, on the investor side. Rather than backing a single startup and hoping it survives, investors in Catalyze put money in at the holding level and receive perpetual ownership of the firm's current and future portfolio companies, plus founder's equity. It behaves less like a single venture bet and more like an index of corporate carve-outs - and the firm markets it as a lower-risk, better-priced alternative to traditional venture and private equity.
The economics follow from the sourcing. A technology that arrives with years of prior corporate investment behind it does not need to be discovered or de-risked from scratch; the expensive early stages have already been paid for by someone else. That is what lets Catalyze describe its entry point as early-stage in valuation but mature in readiness. The firm's job is to supply the three things a corporate lab usually cannot: a dedicated operating team, outside capital, and a go-to-market plan aimed at the technology's real customers rather than the parent company's.
02 / The CustomersA two-sided business
Catalyze serves two audiences at once. On one side sit the innovators: Fortune 100 and Fortune 50 corporations and defense contractors sitting on research they have no path to sell. For them, Catalyze offers three routes - Expand Possibilities (adapting a technology into larger markets), Monetize Underperforming Assets, and Accelerate Strategic Products. In each case the corporation offloads operational risk while still capturing value from work already paid for.
On the other side sit the investors, who get access to technologies that never reach traditional venture channels - innovations carrying significant prior corporate investment, which lowers early startup costs and shortens time to market. The pitch is exclusivity: you cannot find these deals on a demo day, because they were never meant to leave the building.
The two sides reinforce each other. Corporations are more willing to hand over a sensitive technology to a firm that can prove it will be run by capable operators and funded properly; investors are more willing to commit to a firm with a repeatable pipeline of vetted corporate assets. Catalyze positions itself as the trusted middle - the party both sides can deal with because it speaks the language of the Fortune 100 boardroom and the startup operating floor at the same time.
03 / The FoundersOperators, not spectators
Tricia and Joe D'Cruz founded the firm in 2014 and still run it as managing directors. Joe's background spans senior roles at DuPont, Nokia Networks and EDS/HP, along with a string of startups; he serves as executive chairman of Alpine Advanced Materials and on the board of Metro Aerospace. Tricia's three-decade career includes leading Tekelec's Switching Solutions Group, an executive role at Efficient Networks (which went public and was later acquired by Siemens), and founding a strategy consulting firm; she chairs Almaden Genomics. The pattern is consistent: they do not just write checks into the portfolio companies, they take operating seats inside them.
04 / The PortfolioFour companies, four industries
The clearest way to understand Catalyze is to look at what it has already built. The spinouts share no single market - which is the point. They share a pedigree.
Metro Aerospace / 2017
Makes Microvanes - small, 3D-printed aerodynamic components that reshape an aircraft's tail section to cut drag and fuel consumption, for both military and commercial aviation.
Alpine Advanced Materials / 2019
Commercialized a roughly $50M advanced material originally developed for the F-35 program, adapting custom-engineered lightweight parts for aerospace, space, defense and transportation.
Almaden Genomics / 2022
Offers g.nome, a cloud-native platform that accelerates genomic research and drug discovery. It began as an internal startup inside IBM's Almaden Research Center before being spun out.
Axcend / 2024
Builds compact, portable liquid chromatography systems - "HPLC Anywhere" - that let scientists bring the lab to the sample for pharmaceuticals, petrochemicals and environmental monitoring.
05 / The EdgeWhy it is hard to copy
Plenty of firms talk about technology transfer. What separates Catalyze is access and credibility, and both trace to who is in the room. The firm is operator-led rather than analyst-led: managing directors who have run real businesses, a partner CFO who has built finance teams at startups and Fortune 50 companies, and an advisory board that reads like a defense and aerospace reunion.
That board is not decoration. It includes two former heads of Lockheed Martin's Skunk Works, a retired US Air Force Chief of Staff, and a former Undersecretary of Defense for Research and Engineering, alongside former BCG Digital Ventures leaders and a former CEO of Elbit America. When your business depends on being trusted with a corporation's or a government program's most sensitive technology, that network is the moat.
It also shapes what Catalyze looks for. The portfolio's center of gravity - aerospace, defense-derived materials, scientific instruments, genomics - is not an accident; it maps to where the team's expertise and relationships are deepest. A firm without that bench could read a term sheet, but it could not credibly judge whether a defense material will hold up in a commercial supply chain, or whether a shrunken chromatography system is a lab curiosity or a real product. That judgment, applied hundreds of times a year against assets most investors never see, is the part of the model that does not show up on a cap table.
06 / The MarketWhere it fits
Catalyze sits in the gap between several familiar categories. It is not quite a traditional venture fund, because it does not chase pre-product founders. It is not classic private equity, because it builds companies rather than buying cash-flowing ones. And it is not a university or federal tech-transfer office, because it takes operational control. Its closest cousins are corporate venture arms and venture studios, but even those rarely start from proven Fortune 100 assets and hand investors ownership of the entire portfolio.
That positioning got a name in November 2023, when the firm dropped "Dallas" to become Catalyze Partners - signaling a global focus and an explicit identity as an alternative investment vehicle rather than a local accelerator. The recognition followed: in March 2025, Tricia and Joe D'Cruz were named 2025 Dealmakers of the Year at the Smart Business Dealmakers Conference in Dallas, largely on the strength of the Axcend deal.
The wager underneath all of it is a simple observation about how large organizations work. The bigger a company gets, the more good ideas it has to kill - not because they are bad, but because they do not fit. Catalyze treats that mismatch as an asset class. It buys after the science is settled and before the market notices, which is a narrow window, but a real one. Whether it becomes a durable category or a well-timed niche will depend on how many of those $100 million businesses it can actually build.